SAN FRANCISCO--(BUSINESS WIRE)--Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced positive results from its recently completed pilot Phase 2 clinical trial of vocacapsaicin in patients undergoing open laparotomy for ventral hernia repair. Vocacapsaicin is a first-in-class, non-opioid, long-lasting therapeutic with FDA Breakthrough Therapy Designation that is administered as a single dose during surgery. The primary objectives of the study, conducted in 24 patients, were to evaluate the effects of vocacapsaicin over 7 days on reported pain with activity, pain at rest, and opioid consumption, as well as safety and pharmacokinetics.
SAN FRANCISCO--(BUSINESS WIRE)--Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced two important Phase 3 clinical relationships for its lead product candidate, vocacapsaicin.